PKI166 is an experimental, reversible inhibitor of epidermal growth factor receptor tyrosine kinase. References: Hoekstra R, Dumez H, Eskens FA, van der Gaast A, Planting AS, de Heus G, Sizer KC, Ravera C, Vaidyanathan S, Bucana C, Fidler IJ, van Oosterom AT, Verweij J. Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6908-15. PubMed PMID: 16203782.

纯度：≥98%

CAS：187724-61-4